-
Selpercatinib, sold
under the
brand name
Retevmo among others, is a
targeted medication for the
treatment of
cancers in
people whose tumors have an alteration...
-
selective RET inhibitors.
Around 2017, the
first selective RET
inhibitors selpercatinib (LOXO-292) and
pralsetinib (BLU-667)
started their first phase I/II...
-
Capmatinib L01EX18
Avapritinib L01EX19
Ripretinib L01EX21
Tepotinib L01EX22
Selpercatinib L01EX23
Pralsetinib L01EX24
Surufatinib L01EX25
Umbralisib L01EX26 Sitravatinib...
- been
approved for
medical use
include Pembrolizumab, Larotrectinib,
Selpercatinib, Entrectinib, and Pralsetinib.
Pembrolizumab was
approved by the US...
-
targeting RET-driven malignancies,
newer selective inhibitors (such as
selpercatinib and pralsetinib) have
shown significant activity in both
mutations and...
-
Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
Repifermin Selpercatinib Trafermin Velafermin FGFR2 Agonists:
Ersofermin FGF (1, 2 (bFGF), 3...
-
Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
Repifermin Selpercatinib Trafermin Velafermin FGFR2 Agonists:
Ersofermin FGF (1, 2 (bFGF), 3...
-
Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
Repifermin Selpercatinib Trafermin Velafermin FGFR2 Agonists:
Ersofermin FGF (1, 2 (bFGF), 3...
-
Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
Repifermin Selpercatinib Trafermin Velafermin FGFR2 Agonists:
Ersofermin FGF (1, 2 (bFGF), 3...
-
Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
Repifermin Selpercatinib Trafermin Velafermin FGFR2 Agonists:
Ersofermin FGF (1, 2 (bFGF), 3...
